BioSenic S.A. (BR:BIOS) — Market Cap & Net Worth
Market Cap & Net Worth: BioSenic S.A. (BIOS)
BioSenic S.A. (BR:BIOS) has a market capitalization of $1.57 Million (€1.34 Million) as of May 4, 2026. Listed on the BR stock exchange, this Belgium-based company holds position #29902 globally and #110 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioSenic S.A.'s stock price €0.00 by its total outstanding shares 652862279 (652.86 Million). Analyse BioSenic S.A. cash conversion from operations to see how efficiently the company converts income to cash.
BioSenic S.A. Market Cap History: 2015 to 2026
BioSenic S.A.'s market capitalization history from 2015 to 2026. Data shows change from $14.88 Billion to $1.68 Million (-58.03% CAGR).
Index Memberships
BioSenic S.A. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
BEL All Share
BSPT
|
$806.02 Billion | 0.00% | #106 of 108 |
|
CAC Health Care
FRHC
|
$262.01 Billion | 0.00% | #33 of 36 |
Weight: BioSenic S.A.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
BioSenic S.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioSenic S.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
86.03x
BioSenic S.A.'s market cap is 86.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $14.88 Billion | $1.70 Million | -$14.14 Million | 8745.46x | N/A |
| 2017 | $5.93 Billion | $41.00K | -$12.75 Million | 144647.95x | N/A |
| 2018 | $3.43 Billion | $1.00 Million | -$14.22 Million | 3434.69x | N/A |
| 2020 | $1.98 Billion | $1.00 Million | -$11.94 Million | 1984.49x | N/A |
| 2021 | $508.33 Million | $312.00K | -$984.00K | 1629.28x | N/A |
| 2022 | $73.27 Million | $296.00K | -$2.04 Million | 247.55x | N/A |
| 2023 | $46.71 Million | $543.00K | -$28.78 Million | 86.03x | N/A |
Competitor Companies of BIOS by Market Capitalization
Companies near BioSenic S.A. in the global market cap rankings as of May 4, 2026.
Key companies related to BioSenic S.A. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
BioSenic S.A. Historical Marketcap From 2015 to 2026
Between 2015 and today, BioSenic S.A.'s market cap moved from $14.88 Billion to $ 1.68 Million, with a yearly change of -58.03%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.68 Million | -4.35% |
| 2025 | €1.76 Million | -60.34% |
| 2024 | €4.43 Million | -90.52% |
| 2023 | €46.71 Million | -36.25% |
| 2022 | €73.27 Million | -85.59% |
| 2021 | €508.33 Million | -74.38% |
| 2020 | €1.98 Billion | -28.67% |
| 2019 | €2.78 Billion | -19.00% |
| 2018 | €3.43 Billion | -42.08% |
| 2017 | €5.93 Billion | -0.19% |
| 2016 | €5.94 Billion | -60.06% |
| 2015 | €14.88 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of BioSenic S.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.57 Million USD |
| MoneyControl | $1.57 Million USD |
| MarketWatch | $1.57 Million USD |
| marketcap.company | $1.57 Million USD |
| Reuters | $1.57 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BioSenic S.A.
BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Pha… Read more